Werewolf Therapeutics, Inc. Common Stock
HOWLStock
$0.37−74.08%52W
Market Cap$17.88M
P/E—
Div yield—
Beta0.29
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-56.53%
Price vs S&P 500 (4W)-6.29%
VGM Score15.73
Market Capitalization$17.88M
Earnings Surprise History
Q1 26-0.28est. -0.29
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.17
4.27
4.20
4.20
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
HOWLWerewolf Therapeutics, Inc. Common Stock | — | — | F | $0.37 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Werewolf Therapeutics develops cancer immunotherapies using its proprietary PREDATOR platform to engineer conditionally activated molecules. The company's INDUKINE molecules remain inactive in healthy tissue but selectively activate immune responses within the tumor microenvironment, potentially addressing the side-effect limitations of conventional immunotherapies. This targeted approach aims to combine improved therapeutic efficacy with reduced systemic toxicity.